# Bunge Global SA (BG)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-28  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/BG/primer

## Business Model

---
source: coverage-next-full
ticker: BG
step: 01
title: Business Model (Overview)
date: 2026-05-28
---

### Step 01 — Business Model

#### Key Findings

- **What BG does (one line):** Bunge Global is the world's largest oilseed processor by capacity and, post-Viterra, one of the four dominant global grain merchants, monetizing the spread between farmer-origination prices and downstream food/feed/fuel demand [S1][S2].
- **Operating model is dual-layer:** (1) an asset-heavy industrial business — crush plants, port elevators, refineries — earning margin on physical throughput; (2) a commercial trading book — origination basis, freight, futures, and biofuel arbitrage — that can swing quarterly EBIT by hundreds of millions [S3].
- **Four reporting segments post-Viterra (effective Q3 2025):** Soybean Processing & Refining, Softseed Processing & Refining, Tropical Oils & Specialty Ingredients, Grain Merchandising & Milling [S4]. Q1 2026 segment Adj EBIT contribution was 57%/30%/7%/7% respectively — heavily soybean-led.
- **Value-chain position:** BG sits in layers 1-4 (origination, logistics, processing, refining); it does **not** operate downstream branded consumer foods (unlike ADM Nutrition or Cargill's specialty ingredient lines), nor upstream farm ownership [S5].
- **Net read: MIXED-POSITIVE for thesis.** Scale is now unmatched globally in oilseed processing; the strategic gap vs ADM is the lighter downstream specialty footprint. Bull case: synergies + biofuel pull-through. Bear case: commodity-cycle exposure with diluted equity base.

#### Implications for Thesis and Valuation

- BG is fundamentally a **spread business**, not a fee/recurring-revenue model. Valuation framework must accept cyclical earnings.
- The post-Viterra entity is more grain-merchandising-tilted than the standalone Bunge of 2019-2024 — closer in shape to ADM than to a pure crushing comp.
- **The biggest valuation lever** is the next-3-years average mid-cycle crush margin assumption (highly sensitive — modeled in Step 14 of /complete-coverage).
- BG's earnings are NOT linear / extrapolable from any single year; CY2023 was a high-margin year ($14.87 GAAP EPS), CY2024 was trough ($7.99), CY2025 reported ($4.91 GAAP / $7.57 adj) reflects integration drag.

#### Objective

Describe what Bunge does in plain language, map its value-chain position, identify revenue streams and economics, document the segment structure post-Viterra, and frame the operating-vs-trading split that drives quarterly variance.

#### Narrative Analysis

##### What BG actually does

In any given month, Bunge:
1. **Buys** raw oilseeds (mostly soybeans, canola, sunflower seed) and grains (wheat, corn) from farmers in Brazil, Argentina, US Midwest, Canada, EU, Black Sea, and Australia — increasingly so via Viterra's elevator network.
2. **Moves** them via owned-and-leased port terminals, river barges, rail, and trucks — the logistical optimization across origin/destination pairs being one of the trading book's main P&L levers.
3. **Crushes** oilseeds into vegetable oil + protein meal at ~75-80 plants worldwide.
4. **Refines** crude vegetable oil into branded/private-label cooking oils, bottled oils, margarine bases, biofuel feedstock.
5. **Mills** wheat and corn into flour and dry-mill products.
6. **Sells** to: food manufacturers (Nestle, Unilever, P&G's food brands, Procter & Gamble, Cargill itself for further processing), animal feed mills, foodservice distributors, biofuel producers (Chevron under the JV, plus arm's-length sales to Phillips 66, Marathon, Valero), and end-customers via private-label oils [S1].

##### Layered value-chain map

```
Layer 1: Origination — farmer-facing, basis-pricing
   ↓ (Bunge legacy: light; Viterra: heavy)
Layer 2: Logistics — port elevators, river/rail/truck, storage
   ↓ (Bunge + Viterra combined)
Layer 3: Processing — crush plants (oilseeds), mills (wheat/corn)
   ↓ (Bunge core competency, largest globally post-Viterra)
Layer 4: Refining & Distribution — refined oils, lecithin, specialty ingredients
   ↓ (Bunge: present; ADM: deeper)
Layer 5: Branded Consumer / Specialty — NOT operated by BG
```

[S1][S5]

##### Revenue streams

BG's segment structure post-Viterra (effective Q3 2025) [S4]:

| Segment | What it sells | Q1 2026 Revenue | Q1 2026 Adj EBIT | EBIT Margin |
|---------|---------------|-----------------|------------------|-------------|
| Soybean Processing & Refining | Soybean oil + soy meal; refined soybean oil | $9,552M | $377M | 3.9% |
| Softseed Processing & Refining | Canola, sunflower, rapeseed → oil + meal; refined oils | $3,904M | $195M | 5.0% |
| Tropical Oils & Specialty Ingredients | Palm, coconut, specialty oils, lecithin, soy protein concentrates | $1,228M | $45M | 3.7% |
| Grain Merchandising & Milling | Origination, trading, port elevators, wheat/corn milling | $7,177M | $44M | 0.6% |
| **Total** | | **$21,861M** | **$661M (Adj segment EBIT)** | **3.0%** |

[S4]

##### Operating-vs-trading split

A single Q1 reading suggests that BG's processing segments earn ~3-5% segment Adj EBIT margins from physical throughput, while the Grain Merchandising & Milling segment runs at ~0-1% margin most of the time because it's effectively a **flow business**: high revenue (port + elevator + trading throughput), low fixed margin per ton, with EBIT swinging when basis spreads or freight arbs open up. This is a fundamental difference from pure-play food companies — BG's trading book is a real risk and earnings line, not back-office hedging [S6].

##### The Chevron JV (Bunge Chevron Ag Renewables)

50/50 joint venture with Chevron. Bunge contributed soybean processing facilities in Destrehan, LA and Cairo, IL; Chevron contributed ~$600M cash. Capacity goal: expand from 7,000 tons/day (end 2024) to ~14,000 tons/day by end 2026. Sells low-CI soybean oil to Chevron's renewable diesel refineries. This is **equity-method** consolidation (not part of BG's reported revenue), but it is a strategic optionality on US biofuel mandates [S7]. **Secondary track applies here:** this asset is best valued via standard DCF / capacity multiples, not commodity-cycle logic.

##### What BG is NOT

- Not a branded consumer foods company (no Mazola/Wesson equivalent at scale within BG; some specialty oils are branded but small)
- Not an agronomy / seed company (no equivalent to Corteva or Bayer Crop Science)
- Not a fertilizer or crop protection player
- Not vertically integrated upstream into farm operations

This shapes the moat assessment: BG's moat — if any — is in scale, geographic optionality, and trading book skill, not in IP or brand. (Tested in Step 10.)

#### Evidence and Sources

- Segment structure and Q1 2026 segment Adj EBIT: company Q1 2026 press release [S4]
- Value-chain position vs ADM: peer comparison and industry analysis [S5]
- Chevron JV mechanics and capacity: 2023 biodieselmagazine + biofuels-news coverage [S7]
- General BG description and post-Viterra commentary [S1][S2][S3]

#### Assumption Register Updates

| ID | Step | Assumption | Type | Value | Unit | Basis | Sensitivity | Source |
|----|------|-----------|------|-------|------|-------|-------------|--------|
| A05 | 01 | BG is a spread/cycle business; valuation must NOT linear-extrapolate any single year | Judgment | — | — | Sector track + segment economics | High | A05 |
| A06 | 01 | Combined entity segment mix: Soy P&R ~45% revenue / 57% Adj EBIT; Softseed ~18%/30%; Tropical ~6%/7%; Grain Merch ~33%/7% | Estimate | — | mix | Q1 2026 segment data | Medium (one-quarter sample) | A06 |
| A07 | 01 | Bunge Chevron JV equity-method; not in consolidated revenue but real strategic asset | Fact | — | — | JV documentation [S7] | Low (yet) | A07 |

#### Tables and Calculations

##### Segment Mix — Q1 2026 (one-quarter sample)

| Segment | Revenue Mix | Adj EBIT Mix | Margin (Adj EBIT / Rev) |
|---------|-------------|--------------|-------------------------|
| Soybean P&R | 43.7% | 57.0% | 3.9% |
| Softseed P&R | 17.9% | 29.5% | 5.0% |
| Tropical Oils & Specialty Ingr | 5.6% | 6.8% | 3.7% |
| Grain Merchandising & Milling | 32.8% | 6.7% | 0.6% |
| **Total** | **100%** | **100%** | **3.0%** |

##### Historic Segment Structure (pre-Q3 2025)

Pre-realignment, Bunge reported as: Agribusiness, Refined & Specialty Oils, Milling, Sugar & Bioenergy. The realignment in Q3 2025 was driven by the Viterra integration and management's combined-company operating view. **Direct comparability for full-year segment series will require restating prior periods — pending in /complete-coverage Step 13 work.**

#### Open Questions and Data Gaps

- Sugar & Bioenergy segment treatment under new 4-segment structure (likely embedded into Grain Merchandising or treated as held-for-sale separately) — to confirm from 10-K segment note
- Customer concentration explicit disclosure
- Geographic mix split by segment (especially South America vs North America)
- Full-year FY2025 segment data not transcribed (only summary press release fragments)

#### Next-Step Dependencies

- Step 02 will use segment structure here for industry/market positioning
- Step 03 will need segment-level margin data for margin tree
- Step 10 will test moat hypothesis using value-chain map

#### Source Index

| Source Tag | Document or URL | Section / Page / Slide | Date | Notes |
|------------|----------------|----------------------|------|-------|
| [S1] | Bunge 10-K FY2025 summary | `BG_financials/sec_filings/10K_FY2025_summary.md` | 2026-05-28 | Business description |
| [S2] | StockAnalysis.com BG | https://stockanalysis.com/stocks/bg/ | 2026-05-28 | Segment / ownership data |
| [S3] | Bunge Q4 2025 + Q1 2026 press releases | `BG_financials/presentations/investor_presentation_2026.md` | 2026-05-28 | Segment commentary |
| [S4] | Bunge Q1 2026 press release | SEC 8-K 000162828026028079 | 2026-04-29 | 4-segment Adj EBIT split |
| [S5] | Competitive landscape | `BG_financials/industry/competitive_landscape.md` | 2026-05-28 | Value-chain peer mapping |
| [S6] | Market overview | `BG_financials/industry/market_overview.md` | 2026-05-28 | Trading vs processing dynamics |
| [S7] | Bunge Chevron JV announcement (2022); biofuelsmagazine 2024 update | https://biodieselmagazine.com/articles/2517732/chevron-bunge-partner-on-renewable-fuel-feedstocks | 2026-05-28 | JV mechanics |

## Financial Snapshot

---
source: coverage-next-full
ticker: BG
step: 04
title: Financial Quality (Snapshot + Adversarial Sweep)
date: 2026-05-28
---

### Step 04 — Financial Quality

#### Key Findings

- **Earnings quality is structurally low** — net income margins of 0.85-7.85% over CY2021-CY2025 with high cycle volatility; FY2025 reported $816M net income vs $2,243M in CY2023 [S1]. The headline EPS is heavily distorted by mark-to-market gains/losses on the trading book, FX, and Viterra purchase accounting.
- **Adjusted EPS is the primary external metric** — Adj EPS strips out non-cash adjustments (commodity hedge mark-to-market, integration charges, certain divestiture gains/losses). CY2025 adj EPS $7.57 vs GAAP $4.91 = 35% difference [S2]. This wedge is structurally large because of the trading book.
- **Cash conversion is poor in the short run but normalizes over the cycle** — CY2025 OCF $844M vs net income $816M (104% conversion looks OK in isolation, but heavy working-capital build offset trading gains); CY2024 OCF $1,900M vs NI $1,137M (168% — normal); CY2022 OCF NEGATIVE $5.5B vs NI $1.6B (negative working-capital absorption during commodity-price spike) [S1].
- **Adversarial sweep finds NO material short reports, NO active SEC enforcement actions, NO material legal/regulatory overhangs.** Bunge has historically been free from accounting-fraud allegations, unlike Glencore (its largest shareholder, with FCPA history). Bunge had a $112M settlement with the DOJ in 2013 for accounting issues at Argentine subsidiary but no recurrence since.
- **Net read: NEUTRAL.** Quality is cycle-typical for the agribusiness oligopoly — neither best-in-class (like the franchise-business comps) nor problematic. The Adj EPS wedge is large but understood by analysts and consistent across peers (ADM has a similar adjustment pattern).

#### Implications for Thesis and Valuation

- Use Adj EPS, not GAAP EPS, for forward valuation (consistent with how the Street prices the stock).
- Discount the trading-book P&L line in forward modeling — treat as zero-NPV mean-reverting, with quarterly variance built into the equity-cost-of-capital.
- The $14.3B net debt post-Viterra is the single largest balance-sheet risk; rating-agency response to be monitored.
- Working-capital cycle (especially South American harvest timing) creates seasonal OCF swings that are normal but real.

#### Objective

Assess earnings quality, accounting conservatism, cash conversion, balance-sheet integrity, and run an adversarial research sweep for short reports, lawsuits, SEC investigations, and other reputational/governance overhangs.

#### Narrative Analysis

##### Earnings quality — GAAP vs Adjusted

Bunge's GAAP earnings include several material items the Street strips out:
- **Mark-to-market on hedge book** — commodity derivatives held for risk-management purposes generate non-cash gains/losses that don't reflect underlying margin
- **FX translation** — large Brazilian, Argentine, EU footprint generates non-cash FX volatility
- **Integration / restructuring charges** — Viterra-related in 2025-2026
- **Bargain purchase / goodwill items**

CY2025 reconciliation:
- GAAP net income: $816M / GAAP diluted EPS: $4.91 [S1]
- Adj net income: ~$1.46B / Adj EPS: $7.57 [S2]
- Wedge: ~$643M ($2.66 per share) of non-cash / non-operating items added back

Historical adj-vs-GAAP wedges (per StockAnalysis-derived back-calcs):
- CY2024: GAAP $7.99 vs adj $9.19 (15% wedge)
- CY2023: GAAP $14.87 vs adj n/d
- CY2025: GAAP $4.91 vs adj $7.57 (54% wedge) — outsized because of Viterra purchase accounting

This pattern is typical of the agribusiness oligopoly. ADM, Wilmar, and LDC all show similar reconciliations. **For valuation, use Adj EPS consistently.**

##### Cash conversion analysis

OCF vs Net Income over the cycle:

| Year | NI ($M) | OCF ($M) | OCF/NI | Working Capital Δ | Note |
|------|---------|----------|--------|-------------------|------|
| CY2021 | 2,078 | -2,894 | NEGATIVE | -$1,156 | Commodity-price ramp absorbed cash |
| CY2022 | 1,610 | -5,549 | NEGATIVE | -$342 (but inventory + AR build heavy) | Same dynamic, peak commodity prices |
| CY2023 | 2,243 | 3,308 | 1.47x | +$897 | Working-capital release |
| CY2024 | 1,137 | 1,900 | 1.67x | -$463 | Normal cycle |
| CY2025 | 816 | 844 | 1.03x | -$503 + Viterra add | Cycle + integration |

[S1][S2]

**The OCF series is dominated by working-capital swings tied to commodity prices**, not earnings quality. When commodity prices spike (2021-2022), inventory and AR balloon → OCF turns deeply negative even as NI is positive. When prices fall, the unwind shows up as OCF release. This is structurally correct given BG's flow-business nature, but it makes any single-year OCF measurement misleading. **Use multi-year OCF averages, not annual snapshots, for cash quality assessment.**

##### Balance sheet integrity

Post-Viterra (Dec 31, 2025):
- Total assets: $44.5B (vs $24.9B pre-merger)
- Net debt: $14.3B (vs $3.8B pre-merger)
- Equity: $17.4B (vs $10.9B pre-merger)
- Net debt / equity: 0.82 (manageable, but materially elevated)
- Goodwill + intangibles: $3.4B (modest; not a write-down risk)
[S2]

The doubling of assets reflects Viterra consolidation; the elevated leverage is the integration period's main rating-agency variable. S&P / Moody's actions are a monitor (likely BBB / Baa2 range; downgrade risk if deleveraging slips).

##### Adversarial Research Sweep

Methodology: searched for short-report distribution (Muddy Waters, Hindenburg, Citron, Quintessential, Wolfpack, etc.), SEC enforcement actions, class-action litigation, and FCPA/anti-corruption matters involving Bunge.

| Type | Finding | Status |
|------|---------|--------|
| Active short reports | None publicly distributed against BG (current cycle) | Clear |
| Historical short reports | None notable in the past decade | Clear |
| SEC enforcement actions | None current | Clear |
| Historical SEC matter | 2013 — Bunge resolved DOJ/SEC investigation of Argentine subsidiary (Bunge Argentina) tax-fraud allegations with $112M settlement | Resolved >12 years ago; no recurrence |
| FCPA matters | None against Bunge | Clear |
| Recent class actions | None material | Clear |
| Major regulatory fines | Routine commodity-trading regulatory matters; nothing material | Clear |
| EUDR (EU Deforestation Regulation) compliance | Bunge has invested in traceability; recent reports show on-track compliance for 2025 effective date | Clear / on-track |
| ESG controversies | Brazilian Cerrado biome soy sourcing has drawn NGO/Greenpeace criticism over the years; Bunge has issued no-deforestation commitments and traceability investments | Ongoing reputation matter — not a financial risk |

**Glencore overhang note:** Bunge's largest shareholder (~15% post-Viterra) is Glencore plc, which has a documented history of FCPA / bribery / regulatory issues across its mining + trading businesses. As far as I can determine, none of this exposure transfers to Bunge directly (the FCPA matters were settled by Glencore plc; no co-defendant designation for Viterra or Bunge in those actions). But Glencore's reputational/governance profile is something a long-only investor should be aware of, even if it has no direct contagion to BG.

##### Key financial-quality flags

1. **Goodwill / intangibles low** — only $3.4B combined vs $44.5B assets — minimal impairment risk
2. **No debt covenant disclosure suggests material headroom; new $XXBn Viterra-funding facility was syndicated 2025
3. **No going-concern language** ever issued
4. **Audit firm — to confirm from latest 10-K** (likely Deloitte or EY, no recent auditor change controversy)
5. **Restatements** — none material in past 5 years

#### Evidence and Sources

- Annual GAAP series [S1]; Adjusted reconciliations from press releases [S2]
- Adversarial sweep results from web search across short-report and litigation sources [S3]
- Glencore reference / non-contagion analysis [S4]

#### Assumption Register Updates

| ID | Step | Assumption | Type | Value | Unit | Basis | Sensitivity | Source |
|----|------|-----------|------|-------|------|-------|-------------|--------|
| A17 | 04 | Use Adj EPS, not GAAP EPS, for forward valuation | Judgment | — | — | Street convention; structural wedge | High | A17 |
| A18 | 04 | Adversarial sweep clean — no active short reports, no SEC actions, no material litigation overhangs | Fact | — | — | Public-data sweep [S3] | Medium | A18 |
| A19 | 04 | Glencore's FCPA / regulatory history does not contagion-transfer to BG; treat as ownership-block governance variable not financial risk | Judgment | — | — | Legal isolation; no co-defendant filings | Low-Medium | A19 |
| A20 | 04 | Use multi-year OCF averages (5-year) for cash-quality assessment, not single-year snapshots | Judgment | — | — | Structural working-capital cycle | Medium | A20 |

#### Tables and Calculations

##### Earnings Quality Summary

| Metric | CY2021 | CY2022 | CY2023 | CY2024 | CY2025 | 5-yr Avg |
|--------|--------|--------|--------|--------|--------|---------|
| Revenue | 59,152 | 67,232 | 59,540 | 53,108 | 70,329 | 61,872 |
| GAAP NI ($M) | 2,078 | 1,610 | 2,243 | 1,137 | 816 | 1,577 |
| GAAP Diluted EPS | $13.64 | $10.51 | $14.87 | $7.99 | $4.91 | $10.38 |
| Adj EPS | n/d | n/d | n/d | $9.19 | $7.57 | $8.38 (2-yr) |
| OCF | -2,894 | -5,549 | 3,308 | 1,900 | 844 | -478 |
| OCF / NI (when positive) | n/a | n/a | 1.47x | 1.67x | 1.03x | 1.4x avg |
| Capex | 399 | 555 | 1,122 | 1,376 | 1,723 | 1,035 |
| FCF (OCF - Capex) | -3,293 | -6,104 | 2,186 | 524 | -879 | -1,513 |
| **FCF/NI multi-year average** | | | | | | mixed but normalizing |

##### Adversarial Sweep — Detailed Searches Run

| Search Query | Findings |
|--------------|----------|
| "Bunge BG short report" | None recent |
| "Bunge SEC investigation" | 2013 Argentina matter (resolved); none current |
| "Bunge class action lawsuit" | Routine commercial disputes; no material securities-fraud cases |
| "Bunge accounting fraud" | None |
| "Bunge FCPA bribery" | None against Bunge; Glencore separate |
| "Bunge deforestation Cerrado" | Reputation matter; not financial |
| "Bunge auditor change resignation" | None |

#### Open Questions and Data Gaps

- Auditor identity confirmation from latest 10-K
- 10-K's risk-factors detail (couldn't retrieve directly; relied on press summaries)
- Specific covenant details on Viterra-financing facility
- EUDR compliance certification confirmation

#### Next-Step Dependencies

- Step 05 will use the adjusted-vs-GAAP framework for quarterly KPI selection
- Step 06 will deepen the balance-sheet / leverage analysis
- Step 14 (in /complete-coverage) will use Adj EPS as the primary multiple input

#### Source Index

| Source Tag | Document or URL | Section / Page / Slide | Date | Notes |
|------------|----------------|----------------------|------|-------|
| [S1] | XBRL company facts summary | `BG_financials/xbrl/xbrl_summary.md` | 2026-05-28 | GAAP annual series |
| [S2] | Bunge Q4 2025 + Q1 2026 press releases | `BG_financials/presentations/investor_presentation_2026.md` + `BG_financials/other/stockanalysis_summary.md` | 2026-05-28 | Adj EPS, BS, cash flow |
| [S3] | Adversarial sweep — web search across short-report and litigation sources | Various (no specific URLs returned material findings) | 2026-05-28 | Clean |
| [S4] | Glencore reference & non-contagion analysis | Public-record review of Glencore FCPA settlements + Bunge co-defendant check | 2026-05-28 | No transfer |

## Recent Catalysts

---
source: coverage-next-full
ticker: BG
step: 12
title: Bull vs Bear (Catalysts)
date: 2026-05-28
---

### Step 12 — Bull / Bear Debate (Catalysts)

> **No transcripts used.** Following the skill's spec for the non-transcript path, the bull/bear analyst debate is inferred from consensus notes, press releases, recent news, the FY26 guidance trajectory, and the segment-level Q1 2026 print rather than full earnings-call discussion.

#### Key Findings

- **The Street is consensus bullish** — 9 reporting analysts with 5 Strong Buy / 3 Buy / 1 Hold / 0 Sell; average price target $142 (15% upside) [S1].
- **The bull case rests on three legs:** (1) Viterra synergy realization on the announced cadence, (2) crush margin recovery as RVO biofuel policy clarifies, (3) deleveraging path restoring earnings quality.
- **The bear case rests on three legs:** (1) cycle risk — soybean / vegetable oil prices remain depressed if RVO disappoints, (2) integration drag persists longer than guided, (3) overlevered balance sheet constrains growth + dividend / buyback ability.
- **The valuation level (~13x forward EPS) is the swing factor** — it's below historical avg ~15x but above peer ADM (~10x), reflecting Viterra-execution optimism. If FY26 prints ~$9.50 Adj EPS and FY27 prints $11+, the multiple expands further; if FY26 disappoints, it compresses sharply.
- **Q1 2026 print itself was the clearest catalyst** — +89% beat vs consensus + guidance raise from $7.50-8.00 to $9.00-9.50 drove the stock from ~$95 (early April) to $124 (late May).
- **Net read: TILT BULLISH NEAR-TERM, BALANCED MEDIUM-TERM.** Q1 print + guidance raise are real positives; the remaining 2026 quarters need to confirm the trajectory.

#### Implications for Thesis and Valuation

- The bull case is in the price at $124 with consensus FY26 at $9.62 and FY27 at $11.26 (~10-11x forward — already below historical multiple)
- For the stock to materially appreciate from here ($150+ target), FY27 needs to exceed $11.50 + multiple stays at 12-13x = $138-150
- For the stock to materially decline from here ($95 area), one of: RVO disappoints + crush margin fades, integration cost overrun, leverage credit-rating action

#### Objective

Frame the bull and bear theses with quantified upside/downside scenarios, identify near-term catalysts that can move the stock, and document thesis-invalidators.

#### Narrative Analysis

##### The Bull Thesis (synthesizing the optimistic case from Q1 2026 print + Street consensus + management messaging)

**Core argument:** BG is at an inflection point. The Viterra integration is delivering ahead of schedule ($70M synergies realized 2025, $190M targeted 2026, $220M run-rate target). Crush margins are recovering from cycle trough (+56% YoY in soybean processing Q1 2026). The combined entity is structurally stronger than pre-merger BG. FY27 EPS power of $11-12+ is achievable at the right cycle.

**Supporting points (per consensus analyst commentary):**
- 5 Strong Buy ratings; average price target $142 (+15% vs $123.83)
- Median target $145 (+17%); high target $150 (+21%)
- Q1 2026 beat consensus by 89% on Adj EPS
- Mgmt raised FY26 guidance from $7.50-8.00 to $9.00-9.50 — material upward revision
- 14 analysts covering — broad institutional interest
- Forward P/E of 12.16 vs historical avg ~15x → multiple expansion available if earnings deliver
- Segment-level signals: Soybean P&R +56% YoY, Softseed +138%, Tropical +96% in Q1
- Synergy capture pace tracking ahead of management's own initial trajectory

**Quantified bull case (price target $150 / +21%):**
- FY27 Adj EPS: $11.50 (above consensus $11.26)
- Multiple: 13x forward (premium to ADM's ~10x reflecting Viterra synergy + biofuel optionality)
- = $149-150 fair value
- ROIC recovers to ~10% (above WACC)
- Deleveraging on track to <3.0x by end-2027
- Glencore lockup releases without overhang

[S1][S2][S3]

##### The Bear Thesis (synthesizing the bearish counterpoints)

**Core argument:** The Viterra deal was expensive at 8.5x pre-synergy EBITDA, dilutive (33% more shares), and the path to value-accretion requires multi-year flawless execution. The 2025-2026 commodity environment was unusually weak (soybean oil glut, China-US trade disruption, biofuel policy uncertainty), and there's no guarantee 2026-2028 will be materially better. Leverage is elevated; if anything goes wrong, BG has limited ability to deploy capital defensively.

**Supporting points:**
- 1 Hold rating in current coverage; no Sell ratings (but the "Hold" matters)
- Forward P/E of 12 is not particularly cheap on a forward earnings number that itself depends on optimistic synergy + margin assumptions
- ROIC currently 3.5% — well below WACC; even FY27E forecast (~8.8%) is barely above
- Net debt $14B; rating-agency action a watch-item
- Buyback runway constrained near-term (~$300M/yr vs $1.1B in FY24)
- ADM's 81% crushing EBIT collapse in FY25 shows what a hostile biofuel policy environment does to the segment
- Brazilian oversupply + Argentine peso volatility create chronic margin pressure
- Glencore monetization risk post-lockup (early 2027)
- Climate change is a long-term structural risk for South American agriculture

**Quantified bear case (price target $95 / -23%):**
- FY27 Adj EPS: $8.50 (below consensus $11.26 — synergies underdeliver, crush margins flat)
- Multiple: 11x forward (further compression on disappointed expectations)
- = $93-95 fair value
- Possible rating downgrade if deleveraging slips
- Dividend cut not likely but buybacks pause

[S1][S2]

##### Near-Term Catalysts (next 12 months)

| Catalyst | Type | Direction | Magnitude |
|----------|------|-----------|-----------|
| Q2 2026 earnings (late July 2026) — first apples-to-apples YoY quarter | Reporting | Either | High |
| Q3 2026 earnings (late October 2026) | Reporting | Either | Medium |
| Q4 2026 + FY guide (Feb 2027) | Reporting | Either | High |
| RVO 2026/2027 rule-setting | Policy | Either (likely positive) | High |
| US-China trade dynamics evolution | Policy | Either | Medium |
| Glencore lockup release start (early 2027) | Capital markets | Negative (overhang) | Medium |
| Investor Day (already held March 2026) | Communication | n/a (passed) | Low |
| Bunge Chevron JV plant expansion completion (end 2026) | Operational | Positive | Low-Medium |
| Credit rating actions | Capital markets | Either | Medium-High |
| South American crop / weather updates | Operational | Either | Medium |

##### Thesis Invalidators

The thesis is invalidated (i.e., long becomes sell or short) if any of these materialize:
- FY26 Adj EPS prints below $8.00 (i.e., guidance miss + guidance cut for FY27)
- Net Debt / EBITDA stays above 4.0x through end-2027 (deleveraging stalls)
- Credit rating cut to BB+ / Ba1 (loss of investment grade)
- Viterra integration impairment charge >$1B (synergy thesis broken)
- RVO mandates cut materially in any forthcoming rule
- Major operational accident at a flagship plant or port

##### What the Q1 2026 Print Told Us

Looking at the Q1 2026 results in this light: 89% beat + guidance raise — that's the strongest possible single-quarter positive signal. It suggests the bull case is currently in the driver's seat. But Q1 is a low-base quarter; the next two prints (Q2 in July 2026, Q3 in October 2026) are what confirm or deny the trajectory.

#### Evidence and Sources

- Consensus + ratings: Consensus document [S1]
- Q1 + Q4 prints: press releases [S2]
- Synergy & guidance: management commentary [S3]
- Peer (ADM) read-throughs: industry coverage [S4]

#### Assumption Register Updates

| ID | Step | Assumption | Type | Value | Unit | Basis | Sensitivity | Source |
|----|------|-----------|------|-------|------|-------|-------------|--------|
| A52 | 12 | Bull case target $150 = 13x $11.50 FY27 EPS | Estimate | $150 | $ | Multiple × EPS [S1][S2] | High | A52 |
| A53 | 12 | Bear case target $95 = 11x $8.50 FY27 EPS | Estimate | $95 | $ | Multiple × EPS [S1][S2] | High | A53 |
| A54 | 12 | Probability-weighted fair value ~$130 (bull 35% + base 45% + bear 20%) | Judgment | $130 | $ | Tilt bullish near-term | High | A54 |

#### Tables and Calculations

##### Three-Scenario Fair Value Bridge

| Scenario | Probability | FY27 Adj EPS | Forward Multiple | Fair Value | Return vs $123.83 |
|----------|-------------|---------------|------------------|------------|---------------------|
| Bull | 35% | $11.50 | 13x | $150 | +21% |
| Base | 45% | $11.26 (consensus) | 12x | $135 | +9% |
| Bear | 20% | $8.50 | 11x | $94 | -24% |
| **Weighted Avg** | | | | **~$129** | +4% |

Implication: at $124, the stock is roughly fairly valued on probability-weighted basis with a slight upward tilt. The Q1 print + guidance raise have already moved the price into "fair" territory; further upside requires Q2-Q3 confirmation of the trajectory.

---

#### Bull Case — 3 bullets

- **Viterra synergies ahead of pace** — $70M realized in just 6 months of 2025 H2 puts the company on a track to exceed $190M FY26 target and possibly reach $250M+ run-rate by end-2027; each $100M synergy = ~$0.40 EPS uplift.
- **Crush margin recovery + biofuel pull-through** — Q1 2026 Soybean P&R +56% YoY and Softseed +138% YoY signal cycle inflection; RVO clarity in 2026-2027 could expand soybean oil demand structurally and lift mid-cycle EBIT by $300-500M.
- **Combined entity at peak scale + geographic optionality** — largest global oilseed processor by capacity, broadest origination footprint, and the Chevron JV embeds free option value on US renewable diesel mandates; mid-cycle ROIC recovery to 10%+ supports $150+ price target on 13x $11.50 FY27 EPS.

#### Bear Case — 3 bullets

- **Cycle + leverage = downside asymmetry** — 4.3x current Net Debt / EBITDA combined with cycle-trough ROIC of 3.5% means any negative surprise (RVO disappointment, BRL crash, integration cost overrun) directly threatens dividend / buyback capacity and possibly investment-grade credit rating.
- **Viterra dilution requires perfect execution** — 33% more shares outstanding mean FY27 EPS of $11+ requires Viterra-combined NOPAT growth of 30%+ vs FY24 standalone — a high bar dependent on synergy realization, crush margin recovery, AND clean integration with no further charges.
- **Multiple already pricing optimism** — at 12x forward EPS the stock is well above ADM's ~10x; the gap reflects Viterra-execution + biofuel optionality already embedded in the price; bear case multiple compression to 11x on $8.50 FY27 EPS gets to $95, down 23%.

#### Open Questions and Data Gaps

- Transcript-level management Q&A (intentionally not available; this skill's main blind spot)
- Specific sensitivity disclosures for FY26 (typically given in investor day, March 2026)
- Synergy-by-source breakdown (cost vs revenue)
- 3-year FY27-FY29 medium-term outlook detail

#### Next-Step Dependencies

- Step 16 will refine the variant-perception view (what the Street is NOT pricing)
- Step 17 will examine institutional / Glencore positioning
- Step 18 will translate this bull/base/bear set into portfolio sizing
- Step 15 (in /complete-coverage) will build out the formal probabilistic scenarios

#### Source Index

| Source Tag | Document or URL | Section / Page / Slide | Date | Notes |
|------------|----------------|----------------------|------|-------|
| [S1] | Consensus | `BG_financials/other/consensus.md` | 2026-05-28 | Ratings + price targets |
| [S2] | Bunge Q1 2026 + Q4 2025 press releases | `BG_financials/presentations/investor_presentation_2026.md` | 2026-04 / 2026-02 | Beat + raise sequence |
| [S3] | Step 07 capital allocation + Step 08 management | `Step_07_capital_allocation.md`, `Step_08_management_quality.md` | 2026-05-28 | Synergy + management |
| [S4] | ADM peer analysis | tikr.com + finviz coverage | 2026-02 | Bear case parallels |

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/bg
- Full research API: GET /api/v1/research/BG/memo
- Coverage universe: /stocks